Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks
Table 2
Comparison of pretreatment factors between patients with and without sustained virological response.
Factors
SVR ( = 26)
Non-SVR ( = 7)
Age (years)
61
60
0.914
Sex (male/female)
13/13
5/2
0.413
Height (cm)
159.6
159.5
0.880
Weight (kg)
62.6
59.9
0.949
BMI
24.4
25.0
0.780
Baseline HCV-RNA (logIU/mL; TaqMan)
6.7
6.5
0.399
Baseline HCV-RNA (logIU/mL; AccuGene)
6.1
5.6
0.215
Baseline HCV core Ag (fmol/L)
4477.4
1524.4
0.330
No response to prior PEG-IFN and ribavirin
1
3
0.023
Fatty liver
6
0
0.301
Cirrhosis
9
6
0.030
Diabetes mellitus
4
1
1.000
IL28B (major/minor)
20/6
1/6
0.005
Core 70 (wild/mutant)
17/8
1/6
0.027
Core 91 (wild/mutant)
18/7
5/2
1.000
WBC (/mm3)
4995
4410
0.450
Hb (g/dL)
14.5
14.5
0.747
Platelets (/mm3)
16.9
12.2
0.099
ALT (IU/L)
49.5
43.0
0.714
γ-GT (IU/L)
33.5
49.0
0.199
Type VI collagen 7S (ng/mL)
4.4
8.1
0.054
Hyaluronic acid (ng/mL)
72.7
367.0
0.048
AFP (ng/mL)
4.1
11.2
0.067
Reduced dose regimen
20
7
0.301
Values are expressed as median. SVR, sustained virological response; BMI, body mass index; HCV, hepatitis C virus; Ag, antigen; IL, interleukin; WBC, white blood cells; Hb, hemoglobin; ALT, alanine aminotransferase; γ-GT, γ-glutamyl transferase; AFP, alpha-fetoprotein.
